Lyell Immunopharma, Inc.

By person

18 insiders · 52 transactions

Insider

Role

Bought

Sold

Net

Holding

Worth

Change

ARCH Venture Fund XIII, L.P. entity

10% owner

$12.50M (1)

—

+$12.50M

1,426,528

$18.12M

+52.0%

ARCH Venture Partners IX, LLC entity

10% owner

$12.50M (1)

—

+$12.50M

37,839,244

$480.56M

+3,932%

Seely Lynn

President and CEO

$106.19K (1)

$437.91K (9)

−$331.72K

63,899

$811.52K

—

FRIEDMAN CATHY

Director

$300.02K (1)

—

+$300.02K

4,119,860

$52.32M

+6.1%

Ramachandra Sumant

Director

$115.22K (1)

—

+$115.22K

200,000

$2.54M

—

Klausner Richard

Director

$94.94K (1)

$203.33K (2)

−$108.38K

7,577,041

$96.23M

+103.6%

Bulis Veronica Sanchez

VP, Corporate Controller

—

$96.91K (6)

−$96.91K

14,799

$187.95K

+56.6%

Newton Charles W.

Chief Financial Officer

$111.62K (1)

$18.11K (3)

+$93.51K

215,306

$2.73M

—

Lee Gary K.

Chief Scientific Officer

—

$89.80K (9)

−$89.80K

16,220

$205.99K

—

Hill Stephen J.

Chief Operating Officer

—

$63.81K (9)

−$63.81K

16,816

$213.56K

—

Shook David

Chief Medical Officer

—

$31.34K (2)

−$31.34K

20,423

$259.37K

+1,942%

BRAWLEY OTIS W

Director

$19.96K (1)

—

+$19.96K

35,640

$452.63K

—

Innovative Cellular Therapeutics Holdings Ltd entity

10% owner

—

$274.30 (2) scheduled

−$274.30

2,818,980

$35.80M

−7.4%

NELSEN ROBERT

Director

—

36,412,716

$462.44M

—

GSK plc entity

10% owner

—

30,253,189

$384.22M

—

Bishop Hans Edgar

Director

—

4,685,614

$59.51M

+56.2%

Lang Matthew

Chief Business Officer

—

162,500

$2.06M

—

Aguirre Jarrad Mattieu

Chief Medical Officer

—

20,279

$257.54K

0.0%

No percentages here. This company's share count has moved by a factor of 15.4 over the window, from 19,211,202 to 295,228,868 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Lyell Immunopharma, Inc.

By person

Individual transactions

What was left out